Comparative Pharmacology
Head-to-head clinical analysis: BENICAR HCT versus VALSARTAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BENICAR HCT versus VALSARTAN.
BENICAR HCT vs VALSARTAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of an angiotensin II receptor blocker (ARB) and a thiazide diuretic. Olmesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume.
Valsartan is an angiotensin II receptor antagonist (ARB) that selectively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
One tablet orally once daily. Available strengths: 40 mg olmesartan / 12.5 mg hydrochlorothiazide, 40 mg olmesartan / 25 mg hydrochlorothiazide. Dose may be titrated after 2-4 weeks based on response.
80-320 mg orally once daily; initial dose typically 80 mg or 160 mg once daily.
None Documented
None Documented
Clinical Note
moderateValsartan + Torasemide
"The risk or severity of adverse effects can be increased when Valsartan is combined with Torasemide."
Clinical Note
moderateValsartan + Etacrynic acid
"The risk or severity of adverse effects can be increased when Valsartan is combined with Etacrynic acid."
Clinical Note
moderateValsartan + Furosemide
"The risk or severity of adverse effects can be increased when Valsartan is combined with Furosemide."
Clinical Note
moderateValsartan + Bumetanide
Olmesartan: Terminal elimination half-life is 10-15 hours, supporting once-daily dosing. Hydrochlorothiazide: Terminal half-life is 5.6-14.8 hours (mean ~10 hours), prolonged in renal impairment.
Terminal elimination half-life is approximately 6 hours (range 4–9 hours) in healthy adults. In patients with hepatic impairment, half-life is similar due to lack of significant metabolism.
Olmesartan: Approximately 50-65% of absorbed dose excreted in urine (10-20% as unchanged drug, remainder as metabolites), 35-50% in feces via biliary excretion. Hydrochlorothiazide: ≥95% excreted renally as unchanged drug.
Primarily eliminated unchanged in feces (83%) via biliary excretion, and approximately 13% in urine as unchanged drug. Renal clearance accounts for ~30% of total clearance.
Category C
Category D/X
ARB + Thiazide Diuretic
ARB
"The risk or severity of adverse effects can be increased when Valsartan is combined with Bumetanide."